Radiation Therapy for Mantle Cell Lymphoma (MCL)

Phase-Based Progress Estimates
Mantle Cell Lymphoma (MCL)+14 More
Radiation Therapy - Radiation
All Sexes
What conditions do you have?

Study Summary

This trial is studying the side effects and best dose of an antibody when given with a TLR9 agonist and radiation therapy for low-grade B-cell NHL.

Eligible Conditions
  • Mantle Cell Lymphoma (MCL)
  • Lymphoma
  • B-Lymphocytes
  • Lymphoma, Follicular
  • Grade 3a Follicular Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Small Lymphocytic Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: up to 96 weeks

Up to 8 weeks
Number of participants experiencing Dose-limiting Toxicities (DLT) within 8 weeks of treatment initiation
Up to 96 weeks
Overall Response Rate (ORR)
up to 96 weeks
Progression-Free Survival (PFS)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Treatment (radiation therapy, SD-101, BMS-986178)
1 of 1

Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: Radiation Therapy · No Placebo Group · Phase 1

Treatment (radiation therapy, SD-101, BMS-986178)Experimental Group · 4 Interventions: Radiation Therapy, TLR9 Agonist SD-101, Laboratory Biomarker Analysis, Anti-OX40 Antibody BMS 986178 · Intervention Types: Radiation, Drug, Other, Biological
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiation Therapy
Completed Phase 3

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 96 weeks

Who is running the clinical trial?

Ronald LevyLead Sponsor
4 Previous Clinical Trials
131 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,005 Previous Clinical Trials
41,301,912 Total Patients Enrolled
36 Trials studying Mantle Cell Lymphoma (MCL)
3,302 Patients Enrolled for Mantle Cell Lymphoma (MCL)

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: November 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.